{"test_cases_lookup_map": {"{\"actual_output\": \"No relevant information available.\", \"context\": null, \"expected_output\": \"Neuralink has received FDA approval for human trials and has begun recruiting participants for studies focused on helping paralyzed individuals control digital devices.\", \"hyperparameters\": null, \"input\": \"What is the current status of Neuralink clinical trials?\", \"retrieval_context\": [\"**Company Name:** NeuroLink Systems Inc.\\n**Founded:** 2011\\n**Founder & CEO:** Dr. Amara Venkatesh\\n**Headquarters:** San Francisco, California\\n**Mission:** To unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\\n\\n---\\n\\n### **Overview**\", \"---\\n\\n### **Recent Milestones**\\n\\n* FDA Breakthrough Device Designation for SynapseBand NeuroRehab Protocol (2022)\\n* Launched **NeuroLink SDK 2.0** for developers (Q2 2023)\\n* Partnered with Meta for brain-controlled VR experiences (Q4 2023)\\n* Closed Series E funding of \\\\$310M led by Andreessen Horowitz & SoftBank Vision Fund (Q1 2024)\\n* Published peer-reviewed results in *Nature Neuroscience*, Vol. 29, Issue 7\\n\\n---\\n\\n### **FAQs**\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": true, "score": 1.0, "reason": "The score is 1.00 because the answer was fully relevant and addressed the question directly without any irrelevant information. Great job staying focused and concise!", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"No relevant information available.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": true, "score": 1.0, "reason": "Great job! There are no contradictions, so the actual output is fully aligned with the retrieval context.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"NeuroLink Systems Inc. received FDA Breakthrough Device Designation for the SynapseBand NeuroRehab Protocol in 2022.\",\n    \"NeuroLink Systems Inc. launched NeuroLink SDK 2.0 for developers in the second quarter of 2023.\",\n    \"NeuroLink Systems Inc. partnered with Meta for brain-controlled VR experiences in the fourth quarter of 2023.\",\n    \"NeuroLink Systems Inc. closed a Series E funding round of $310 million led by Andreessen Horowitz and SoftBank Vision Fund in the first quarter of 2024.\",\n    \"NeuroLink Systems Inc. published peer-reviewed results in Nature Neuroscience, Volume 29, Issue 7.\",\n    \"The company name is NeuroLink Systems Inc.\",\n    \"NeuroLink Systems Inc. was founded in 2011.\",\n    \"The founder and CEO of NeuroLink Systems Inc. is Dr. Amara Venkatesh.\",\n    \"NeuroLink Systems Inc. is headquartered in San Francisco, California.\",\n    \"The mission of NeuroLink Systems Inc. is to unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\"\n] \n \nClaims:\n[] \n \nVerdicts:\n[]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"NeuroLink Systems Inc. is a neurotechnology company pioneering the next generation of brain\\u2013computer interfaces (BCIs). By combining advanced neuroimaging, signal processing, and AI-driven interpretation, NeuroLink enables seamless communication between the human brain and digital systems.\", \"context\": null, \"expected_output\": \"The Neuralink BCI uses ultra-thin threads with electrodes to record neural activity. These threads are surgically implanted by a robot, and the signals are processed by a chip that wirelessly transmits data.\", \"hyperparameters\": null, \"input\": \"How does the Neuralink brain-computer interface work?\", \"retrieval_context\": [\"**Company Name:** NeuroLink Systems Inc.\\n**Founded:** 2011\\n**Founder & CEO:** Dr. Amara Venkatesh\\n**Headquarters:** San Francisco, California\\n**Mission:** To unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\\n\\n---\\n\\n### **Overview**\", \"---\\n\\n### **Overview**\\n\\nNeuroLink Systems Inc. is a neurotechnology company pioneering the next generation of brain\\u2013computer interfaces (BCIs).\\nBy combining advanced neuroimaging, signal processing, and AI-driven interpretation, NeuroLink enables seamless communication between the human brain and digital systems. The company\\u2019s solutions empower patients, clinicians, and innovators to extend cognition, restore neurological function, and build new modes of human\\u2013machine collaboration.\\n\\n---\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": true, "score": 0.75, "reason": "The score is 0.75 because while the answer correctly identifies the company, it does not actually explain how the Neuralink brain-computer interface works, which is what the question asked. The answer is partially relevant but lacks the necessary explanation to be fully relevant.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"NeuroLink Systems Inc. is a neurotechnology company.\",\n    \"The company is pioneering the next generation of brain\u2013computer interfaces (BCIs).\",\n    \"NeuroLink combines advanced neuroimaging, signal processing, and AI-driven interpretation.\",\n    \"NeuroLink enables seamless communication between the human brain and digital systems.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement only identifies the company and does not explain how the Neuralink brain-computer interface works.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": true, "score": 1.0, "reason": "Great job! There are no contradictions, so the actual output is fully faithful to the retrieval context.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"NeuroLink Systems Inc. is a neurotechnology company.\",\n    \"NeuroLink Systems Inc. pioneers the next generation of brain\u2013computer interfaces (BCIs).\",\n    \"NeuroLink Systems Inc. combines advanced neuroimaging, signal processing, and AI-driven interpretation in its technology.\",\n    \"NeuroLink enables communication between the human brain and digital systems.\",\n    \"The company's solutions are designed to empower patients, clinicians, and innovators.\",\n    \"NeuroLink's solutions aim to extend cognition, restore neurological function, and build new modes of human\u2013machine collaboration.\",\n    \"The company is named NeuroLink Systems Inc.\",\n    \"NeuroLink Systems Inc. was founded in 2011.\",\n    \"The founder and CEO of NeuroLink Systems Inc. is Dr. Amara Venkatesh.\",\n    \"NeuroLink Systems Inc. is headquartered in San Francisco, California.\",\n    \"The mission of NeuroLink Systems Inc. is to unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\"\n] \n \nClaims:\n[\n    \"NeuroLink Systems Inc. is a neurotechnology company pioneering the next generation of brain\u2013computer interfaces (BCIs).\",\n    \"NeuroLink combines advanced neuroimaging, signal processing, and AI-driven interpretation.\",\n    \"NeuroLink enables seamless communication between the human brain and digital systems.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"The SynapseBand uses multi-sensor arrays and NeuroLink's NeuralNet Engine to translate thought patterns into digital commands.\", \"context\": null, \"expected_output\": \"Data from Neuralink devices is transmitted wirelessly using Bluetooth technology to external devices like smartphones or computers for processing and control.\", \"hyperparameters\": null, \"input\": \"How is data transmitted from Neuralink devices?\", \"retrieval_context\": [\"---\\n\\n### **Flagship Product: SynapseBand\\u2122**\\n\\nThe SynapseBand is a wearable, non-invasive neural headband that detects and decodes neural activity in real time. It leverages multi-sensor arrays and NeuroLink\\u2019s proprietary NeuralNet Engine\\u2122 to translate thought patterns into actionable digital commands.\\n\\n**Key Features:**\", \"---\\n\\n### **Recent Milestones**\\n\\n* FDA Breakthrough Device Designation for SynapseBand NeuroRehab Protocol (2022)\\n* Launched **NeuroLink SDK 2.0** for developers (Q2 2023)\\n* Partnered with Meta for brain-controlled VR experiences (Q4 2023)\\n* Closed Series E funding of \\\\$310M led by Andreessen Horowitz & SoftBank Vision Fund (Q1 2024)\\n* Published peer-reviewed results in *Nature Neuroscience*, Vol. 29, Issue 7\\n\\n---\\n\\n### **FAQs**\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": false, "score": 0.3333333333333333, "reason": "The score is 0.33 because the answer focused on features and technologies of the SynapseBand, which are unrelated to the data transmission process of Neuralink devices. It did not address the actual question, leading to a low relevancy score.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0.0, "verboseLogs": "Statements:\n[\n    \"The SynapseBand uses multi-sensor arrays.\",\n    \"The SynapseBand uses NeuroLink's NeuralNet Engine.\",\n    \"The device translates thought patterns into digital commands.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The statement describes a feature of the SynapseBand, not how data is transmitted from Neuralink devices.\"\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"This statement refers to a specific engine used by the SynapseBand, not the data transmission process of Neuralink devices.\"\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": true, "score": 1.0, "reason": "Great job! There are no contradictions, so the actual output is fully faithful to the retrieval context.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0.0, "verboseLogs": "Truths (limit=None):\n[\n    \"The SynapseBand is a wearable, non-invasive neural headband.\",\n    \"The SynapseBand detects and decodes neural activity in real time.\",\n    \"The SynapseBand uses multi-sensor arrays.\",\n    \"The SynapseBand uses NeuroLink\u2019s proprietary NeuralNet Engine to translate thought patterns into actionable digital commands.\",\n    \"The SynapseBand NeuroRehab Protocol received FDA Breakthrough Device Designation in 2022.\",\n    \"NeuroLink SDK 2.0 was launched for developers in Q2 2023.\",\n    \"NeuroLink partnered with Meta for brain-controlled VR experiences in Q4 2023.\",\n    \"NeuroLink closed Series E funding of $310M led by Andreessen Horowitz and SoftBank Vision Fund in Q1 2024.\",\n    \"NeuroLink published peer-reviewed results in Nature Neuroscience, Vol. 29, Issue 7.\"\n] \n \nClaims:\n[\n    \"The SynapseBand uses multi-sensor arrays and NeuroLink's NeuralNet Engine to translate thought patterns into digital commands.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"Neuralink faces challenges in development such as ensuring the safety and efficacy of their neural interface technologies, obtaining regulatory approvals, and developing partnerships for commercialization.\", \"context\": null, \"expected_output\": \"Neuralink faces challenges including regulatory approval, ensuring long-term biocompatibility, scaling manufacturing, addressing ethical concerns, and proving clinical efficacy.\", \"hyperparameters\": null, \"input\": \"What challenges does Neuralink face in development?\", \"retrieval_context\": [\"**Company Name:** NeuroLink Systems Inc.\\n**Founded:** 2011\\n**Founder & CEO:** Dr. Amara Venkatesh\\n**Headquarters:** San Francisco, California\\n**Mission:** To unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\\n\\n---\\n\\n### **Overview**\", \"---\\n\\n### **Recent Milestones**\\n\\n* FDA Breakthrough Device Designation for SynapseBand NeuroRehab Protocol (2022)\\n* Launched **NeuroLink SDK 2.0** for developers (Q2 2023)\\n* Partnered with Meta for brain-controlled VR experiences (Q4 2023)\\n* Closed Series E funding of \\\\$310M led by Andreessen Horowitz & SoftBank Vision Fund (Q1 2024)\\n* Published peer-reviewed results in *Nature Neuroscience*, Vol. 29, Issue 7\\n\\n---\\n\\n### **FAQs**\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": true, "score": 1.0, "reason": "The score is 1.00 because the answer was fully relevant and addressed the challenges Neuralink faces in development without including any irrelevant information. Great job staying focused and on-topic!", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"Neuralink faces challenges in development.\",\n    \"Ensuring the safety of their neural interface technologies is a challenge for Neuralink.\",\n    \"Ensuring the efficacy of their neural interface technologies is a challenge for Neuralink.\",\n    \"Obtaining regulatory approvals is a challenge for Neuralink.\",\n    \"Developing partnerships for commercialization is a challenge for Neuralink.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": true, "score": 1.0, "reason": "Great job! There are no contradictions, so the actual output is perfectly faithful to the retrieval context.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"NeuroLink Systems Inc. received FDA Breakthrough Device Designation for the SynapseBand NeuroRehab Protocol in 2022.\",\n    \"NeuroLink Systems Inc. launched NeuroLink SDK 2.0 for developers in the second quarter of 2023.\",\n    \"NeuroLink Systems Inc. partnered with Meta for brain-controlled VR experiences in the fourth quarter of 2023.\",\n    \"NeuroLink Systems Inc. closed Series E funding of $310 million led by Andreessen Horowitz and SoftBank Vision Fund in the first quarter of 2024.\",\n    \"NeuroLink Systems Inc. published peer-reviewed results in Nature Neuroscience, Volume 29, Issue 7.\",\n    \"The company is named NeuroLink Systems Inc.\",\n    \"NeuroLink Systems Inc. was founded in 2011.\",\n    \"The founder and CEO of NeuroLink Systems Inc. is Dr. Amara Venkatesh.\",\n    \"NeuroLink Systems Inc. is headquartered in San Francisco, California.\",\n    \"The mission of NeuroLink Systems Inc. is to unlock the full potential of the human brain through safe, non-invasive neural interface technologies.\"\n] \n \nClaims:\n[\n    \"Neuralink faces challenges in development such as ensuring the safety and efficacy of their neural interface technologies, obtaining regulatory approvals, and developing partnerships for commercialization.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"Data from Neuralink devices is transmitted through secure 5G, Wi-Fi 6, and BLE integration.\", \"context\": null, \"expected_output\": \"Data from Neuralink devices is transmitted wirelessly using Bluetooth technology to external devices like smartphones or computers for processing and control.\", \"hyperparameters\": null, \"input\": \"How is data transmitted from Neuralink devices?\", \"retrieval_context\": [\"---\\n\\n### **Flagship Product: SynapseBand\\u2122**\\n\\nThe SynapseBand is a wearable, non-invasive neural headband that detects and decodes neural activity in real time. It leverages multi-sensor arrays and NeuroLink\\u2019s proprietary NeuralNet Engine\\u2122 to translate thought patterns into actionable digital commands.\\n\\n**Key Features:**\\n\\n* Sensor array: 128-channel dry EEG with adaptive calibration\\n* Latency: <15 ms brain-to-command response time\\n* AI interpretation: Deep-learning\\u2013based decoding for motor, cognitive, and emotional states\\n* Battery life: 22 hours continuous operation\\n* Connectivity: Secure 5G, Wi-Fi 6, and BLE integration\\n* Compatibility: Works across iOS, Android, Windows, and VR/AR ecosystems\\n\\n---\\n\\n### **Technology Platform**\", \"---\\n\\n### **Technology Platform**\\n\\nAt its core, NeuroLink\\u2019s **Cognitive Signal Processing Framework (CSPF)** integrates hybrid EEG-fNIRS sensing, advanced artifact removal, and self-learning AI interpreters. This enables precise brain activity monitoring without invasive implants, with continuous accuracy improvement via federated learning.\\n\\n---\\n\\n### **NeuroCloud\\u2122 Data Platform**\\n\\nAll SynapseBand sessions sync seamlessly to NeuroCloud, a HIPAA-compliant cloud environment.\\n\\n* Clinicians can track patient progress over time.\\n* Developers can build BCI-enabled apps through open APIs.\\n* Patients can manage mental health, focus, and rehabilitation exercises with real-time dashboards.\\n\\nIntegration with EHR systems and platforms like Oculus, Microsoft Mesh, and Apple Vision Pro is supported via HL7 and FHIR.\\n\\n---\\n\\n### **Use Cases**\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": true, "score": 1.0, "reason": "The score is 1.00 because the answer was fully relevant and addressed the question directly without any irrelevant information. Great job staying focused and concise!", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"Data from Neuralink devices is transmitted through secure 5G integration.\",\n    \"Data from Neuralink devices is transmitted through secure Wi-Fi 6 integration.\",\n    \"Data from Neuralink devices is transmitted through secure BLE integration.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": false, "score": 0.0, "reason": "The score is 0.00 because the actual output incorrectly attributes the SynapseBand's data transmission features (secure 5G, Wi-Fi 6, and BLE integration) to Neuralink devices, which directly contradicts the retrieval context.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"The SynapseBand is a wearable, non-invasive neural headband.\",\n    \"The SynapseBand detects and decodes neural activity in real time.\",\n    \"The SynapseBand uses a 128-channel dry EEG sensor array with adaptive calibration.\",\n    \"The SynapseBand has a brain-to-command response time of less than 15 milliseconds.\",\n    \"The SynapseBand uses deep-learning\u2013based AI to decode motor, cognitive, and emotional states.\",\n    \"The SynapseBand has a battery life of 22 hours of continuous operation.\",\n    \"The SynapseBand supports secure 5G, Wi-Fi 6, and BLE connectivity.\",\n    \"The SynapseBand is compatible with iOS, Android, Windows, and VR/AR ecosystems.\",\n    \"NeuroLink\u2019s Cognitive Signal Processing Framework (CSPF) integrates hybrid EEG-fNIRS sensing, advanced artifact removal, and self-learning AI interpreters.\",\n    \"The CSPF enables precise brain activity monitoring without invasive implants.\",\n    \"The CSPF improves accuracy continuously via federated learning.\",\n    \"All SynapseBand sessions sync to NeuroCloud, a HIPAA-compliant cloud environment.\",\n    \"Clinicians can track patient progress over time using NeuroCloud.\",\n    \"Developers can build BCI-enabled apps through open APIs provided by NeuroCloud.\",\n    \"Patients can manage mental health, focus, and rehabilitation exercises with real-time dashboards on NeuroCloud.\",\n    \"NeuroCloud supports integration with EHR systems and platforms like Oculus, Microsoft Mesh, and Apple Vision Pro via HL7 and FHIR.\"\n] \n \nClaims:\n[\n    \"Data from Neuralink devices is transmitted through secure 5G, Wi-Fi 6, and BLE integration.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The retrieval context states that the SynapseBand, not Neuralink devices, transmits data through secure 5G, Wi-Fi 6, and BLE integration. The claim incorrectly attributes this feature to Neuralink devices.\"\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"Neuralink faces challenges in development such as ensuring accuracy of the thought-to-command system, building a platform for developers to create apps, and maintaining partnerships with research hospitals.\", \"context\": null, \"expected_output\": \"Neuralink faces challenges including regulatory approval, ensuring long-term biocompatibility, scaling manufacturing, addressing ethical concerns, and proving clinical efficacy.\", \"hyperparameters\": null, \"input\": \"What challenges does Neuralink face in development?\", \"retrieval_context\": [\"**Q: How accurate is the thought-to-command system?**\\nA: Independent trials report 93\\u201396% accuracy across motor intention, focus detection, and emotional state classification.\\n\\n**Q: Can developers build apps for the platform?**\\nA: Yes, through the NeuroLink SDK and open API marketplace.\\n\\n---\\n\\n### **Media Contacts**\\n\\n[press@neurolink.com](mailto:press@neurolink.com)\\n[investors@neurolink.com](mailto:investors@neurolink.com)\\n\\n---\\n\\n**Company Motto:** *\\u201cWhere Thought Meets Possibility\\u2122\\u201d*\", \"---\\n\\n### **Use Cases**\\n\\n* **Neurorehabilitation:** Assist stroke and spinal cord patients in regaining motor control\\n* **Mental Health:** Monitor and modulate stress, anxiety, and cognitive fatigue\\n* **Education & Training:** Enhance learning through focus optimization and neurofeedback\\n* **Gaming & VR:** Enable thought-controlled interactions in immersive environments\\n* **Workplace Productivity:** Cognitive load monitoring and brain-state optimization\\n\\n---\\n\\n### **Corporate Structure**\\n\\nNeuroLink employs over 1,200 professionals spanning neuroscience, machine learning, hardware engineering, clinical research, and cloud security. The company collaborates with over 45 research hospitals and maintains labs in the U.S., Europe, and Japan.\\n\\n---\\n\\n### **Leadership**\\n\\n* **Dr. Amara Venkatesh** \\u2013 Founder & CEO\\n* **Dr. Julian Ortega** \\u2013 Chief Neuroscience Officer\\n* **Maya Li** \\u2013 VP, AI & Data Science\\n* **Elena Kovacs** \\u2013 Director of Clinical Partnerships\\n* **David Singh** \\u2013 General Counsel\\n\\n---\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": true, "score": 1.0, "reason": "The score is 1.00 because the answer was fully relevant and addressed the challenges Neuralink faces in development without including any irrelevant information. Great job staying focused and on-topic!", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0.0, "verboseLogs": "Statements:\n[\n    \"Neuralink faces challenges in development.\",\n    \"Ensuring accuracy of the thought-to-command system is a challenge.\",\n    \"Building a platform for developers to create apps is a challenge.\",\n    \"Maintaining partnerships with research hospitals is a challenge.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": true, "score": 1.0, "reason": "The score is 1.00 because there are no contradictions listed, indicating the actual output aligns perfectly with the retrieval context. Great job staying faithful to the source!", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0.0, "verboseLogs": "Truths (limit=None):\n[\n    \"NeuroLink employs over 1,200 professionals.\",\n    \"NeuroLink's staff includes experts in neuroscience, machine learning, hardware engineering, clinical research, and cloud security.\",\n    \"NeuroLink collaborates with over 45 research hospitals.\",\n    \"NeuroLink maintains labs in the U.S., Europe, and Japan.\",\n    \"Dr. Amara Venkatesh is the Founder and CEO of NeuroLink.\",\n    \"Dr. Julian Ortega is the Chief Neuroscience Officer at NeuroLink.\",\n    \"Maya Li is the VP of AI & Data Science at NeuroLink.\",\n    \"Elena Kovacs is the Director of Clinical Partnerships at NeuroLink.\",\n    \"David Singh is the General Counsel at NeuroLink.\",\n    \"NeuroLink's thought-to-command system has an independently reported accuracy of 93\u201396% for motor intention, focus detection, and emotional state classification.\",\n    \"Developers can build apps for the NeuroLink platform using the NeuroLink SDK and open API marketplace.\",\n    \"NeuroLink's use cases include neurorehabilitation, mental health, education and training, gaming and VR, and workplace productivity.\",\n    \"NeuroLink's company motto is 'Where Thought Meets Possibility\u2122'.\",\n    \"Media contacts for NeuroLink include press@neurolink.com and investors@neurolink.com.\"\n] \n \nClaims:\n[\n    \"Neuralink faces challenges in development such as ensuring accuracy of the thought-to-command system, building a platform for developers to create apps, and maintaining partnerships with research hospitals.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"NeuroLink has not yet conducted any clinical trials, but they have received FDA Breakthrough Device Designation for their SynapseBand NeuroRehab Protocol in 2022.\", \"context\": null, \"expected_output\": \"Neuralink has received FDA approval for human trials and has begun recruiting participants for studies focused on helping paralyzed individuals control digital devices.\", \"hyperparameters\": null, \"input\": \"What is the current status of Neuralink clinical trials?\", \"retrieval_context\": [\"---\\n\\n### **Selected Partnerships**\\n\\n* Mayo Clinic\\n* Stanford Neuroinformatics Lab\\n* Siemens HealthTech\\n* Meta Reality Labs\\n* Tokyo Neurological Institute\\n\\n---\\n\\n### **Recent Milestones**\\n\\n* FDA Breakthrough Device Designation for SynapseBand NeuroRehab Protocol (2022)\\n* Launched **NeuroLink SDK 2.0** for developers (Q2 2023)\\n* Partnered with Meta for brain-controlled VR experiences (Q4 2023)\\n* Closed Series E funding of \\\\$310M led by Andreessen Horowitz & SoftBank Vision Fund (Q1 2024)\\n* Published peer-reviewed results in *Nature Neuroscience*, Vol. 29, Issue 7\\n\\n---\\n\\n### **FAQs**\\n\\n**Q: Is SynapseBand safe for everyday use?**\\nA: Yes. SynapseBand is non-invasive, FDA-cleared for clinical use, and has passed IEC 60601 safety standards.\\n\\n**Q: Can SynapseBand be used outside hospitals?**\\nA: Absolutely. SynapseBand is available for both clinical and consumer wellness markets.\", \"---\\n\\n### **Use Cases**\\n\\n* **Neurorehabilitation:** Assist stroke and spinal cord patients in regaining motor control\\n* **Mental Health:** Monitor and modulate stress, anxiety, and cognitive fatigue\\n* **Education & Training:** Enhance learning through focus optimization and neurofeedback\\n* **Gaming & VR:** Enable thought-controlled interactions in immersive environments\\n* **Workplace Productivity:** Cognitive load monitoring and brain-state optimization\\n\\n---\\n\\n### **Corporate Structure**\\n\\nNeuroLink employs over 1,200 professionals spanning neuroscience, machine learning, hardware engineering, clinical research, and cloud security. The company collaborates with over 45 research hospitals and maintains labs in the U.S., Europe, and Japan.\\n\\n---\\n\\n### **Leadership**\\n\\n* **Dr. Amara Venkatesh** \\u2013 Founder & CEO\\n* **Dr. Julian Ortega** \\u2013 Chief Neuroscience Officer\\n* **Maya Li** \\u2013 VP, AI & Data Science\\n* **Elena Kovacs** \\u2013 Director of Clinical Partnerships\\n* **David Singh** \\u2013 General Counsel\\n\\n---\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": true, "score": 1.0, "reason": "The score is 1.00 because the answer was fully relevant and addressed the question directly without any irrelevant information. Great job staying focused and concise!", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0.0, "verboseLogs": "Statements:\n[\n    \"NeuroLink has not yet conducted any clinical trials.\",\n    \"NeuroLink received FDA Breakthrough Device Designation for their SynapseBand NeuroRehab Protocol in 2022.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": false, "score": 0.5, "reason": "The score is 0.50 because the actual output contradicts the retrieval context by not acknowledging that SynapseBand is FDA-cleared for clinical use and that NeuroLink collaborates with over 45 research hospitals, implying clinical trials have been conducted.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0.0, "verboseLogs": "Truths (limit=None):\n[\n    \"NeuroLink has partnerships with Mayo Clinic, Stanford Neuroinformatics Lab, Siemens HealthTech, Meta Reality Labs, and Tokyo Neurological Institute.\",\n    \"SynapseBand NeuroRehab Protocol received FDA Breakthrough Device Designation in 2022.\",\n    \"NeuroLink launched NeuroLink SDK 2.0 for developers in Q2 2023.\",\n    \"NeuroLink partnered with Meta for brain-controlled VR experiences in Q4 2023.\",\n    \"NeuroLink closed Series E funding of $310M led by Andreessen Horowitz and SoftBank Vision Fund in Q1 2024.\",\n    \"NeuroLink published peer-reviewed results in Nature Neuroscience, Vol. 29, Issue 7.\",\n    \"SynapseBand is non-invasive, FDA-cleared for clinical use, and has passed IEC 60601 safety standards.\",\n    \"SynapseBand is available for both clinical and consumer wellness markets.\",\n    \"NeuroLink employs over 1,200 professionals in neuroscience, machine learning, hardware engineering, clinical research, and cloud security.\",\n    \"NeuroLink collaborates with over 45 research hospitals.\",\n    \"NeuroLink maintains labs in the U.S., Europe, and Japan.\",\n    \"Dr. Amara Venkatesh is the Founder and CEO of NeuroLink.\",\n    \"Dr. Julian Ortega is the Chief Neuroscience Officer at NeuroLink.\",\n    \"Maya Li is the VP of AI & Data Science at NeuroLink.\",\n    \"Elena Kovacs is the Director of Clinical Partnerships at NeuroLink.\",\n    \"David Singh is the General Counsel at NeuroLink.\"\n] \n \nClaims:\n[\n    \"NeuroLink has not yet conducted any clinical trials.\",\n    \"NeuroLink received FDA Breakthrough Device Designation for their SynapseBand NeuroRehab Protocol in 2022.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"The retrieval context states that SynapseBand is FDA-cleared for clinical use and that NeuroLink collaborates with over 45 research hospitals, which implies that clinical trials have been conducted.\"\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"The Neuralink brain-computer interface works by implanting a device into the brain that can detect and interpret neural signals. These signals are then translated into commands that can be used to control external devices or applications.\", \"context\": null, \"expected_output\": \"The Neuralink BCI uses ultra-thin threads with electrodes to record neural activity. These threads are surgically implanted by a robot, and the signals are processed by a chip that wirelessly transmits data.\", \"hyperparameters\": null, \"input\": \"How does the Neuralink brain-computer interface work?\", \"retrieval_context\": [\"**Q: How accurate is the thought-to-command system?**\\nA: Independent trials report 93\\u201396% accuracy across motor intention, focus detection, and emotional state classification.\\n\\n**Q: Can developers build apps for the platform?**\\nA: Yes, through the NeuroLink SDK and open API marketplace.\\n\\n---\\n\\n### **Media Contacts**\\n\\n[press@neurolink.com](mailto:press@neurolink.com)\\n[investors@neurolink.com](mailto:investors@neurolink.com)\\n\\n---\\n\\n**Company Motto:** *\\u201cWhere Thought Meets Possibility\\u2122\\u201d*\", \"---\\n\\n### **Use Cases**\\n\\n* **Neurorehabilitation:** Assist stroke and spinal cord patients in regaining motor control\\n* **Mental Health:** Monitor and modulate stress, anxiety, and cognitive fatigue\\n* **Education & Training:** Enhance learning through focus optimization and neurofeedback\\n* **Gaming & VR:** Enable thought-controlled interactions in immersive environments\\n* **Workplace Productivity:** Cognitive load monitoring and brain-state optimization\\n\\n---\\n\\n### **Corporate Structure**\\n\\nNeuroLink employs over 1,200 professionals spanning neuroscience, machine learning, hardware engineering, clinical research, and cloud security. The company collaborates with over 45 research hospitals and maintains labs in the U.S., Europe, and Japan.\\n\\n---\\n\\n### **Leadership**\\n\\n* **Dr. Amara Venkatesh** \\u2013 Founder & CEO\\n* **Dr. Julian Ortega** \\u2013 Chief Neuroscience Officer\\n* **Maya Li** \\u2013 VP, AI & Data Science\\n* **Elena Kovacs** \\u2013 Director of Clinical Partnerships\\n* **David Singh** \\u2013 General Counsel\\n\\n---\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": true, "score": 1.0, "reason": "The score is 1.00 because the answer was fully relevant and addressed the question directly without any irrelevant information. Great job staying focused and informative!", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"The Neuralink brain-computer interface works by implanting a device into the brain.\",\n    \"The device can detect and interpret neural signals.\",\n    \"The neural signals are translated into commands.\",\n    \"The commands can be used to control external devices or applications.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": true, "score": 1.0, "reason": "The score is 1.00 because there are no contradictions\u2014great job staying true to the retrieval context!", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"NeuroLink employs over 1,200 professionals.\",\n    \"NeuroLink's staff includes experts in neuroscience, machine learning, hardware engineering, clinical research, and cloud security.\",\n    \"NeuroLink collaborates with over 45 research hospitals.\",\n    \"NeuroLink maintains labs in the U.S., Europe, and Japan.\",\n    \"Dr. Amara Venkatesh is the Founder and CEO of NeuroLink.\",\n    \"Dr. Julian Ortega is the Chief Neuroscience Officer at NeuroLink.\",\n    \"Maya Li is the VP of AI & Data Science at NeuroLink.\",\n    \"Elena Kovacs is the Director of Clinical Partnerships at NeuroLink.\",\n    \"David Singh is the General Counsel at NeuroLink.\",\n    \"Independent trials report 93\u201396% accuracy for NeuroLink's thought-to-command system across motor intention, focus detection, and emotional state classification.\",\n    \"Developers can build apps for the NeuroLink platform using the NeuroLink SDK and open API marketplace.\",\n    \"NeuroLink's use cases include neurorehabilitation, mental health, education and training, gaming and VR, and workplace productivity.\",\n    \"NeuroLink's company motto is 'Where Thought Meets Possibility\u2122'.\",\n    \"Media contacts for NeuroLink include press@neurolink.com and investors@neurolink.com.\"\n] \n \nClaims:\n[\n    \"The Neuralink brain-computer interface works by implanting a device into the brain that can detect and interpret neural signals.\",\n    \"These signals are then translated into commands that can be used to control external devices or applications.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"Data is transmitted from Neuralink devices through the use of multi-sensor arrays and NeuroLink's proprietary NeuralNet Engine.\", \"context\": null, \"expected_output\": \"Data from Neuralink devices is transmitted wirelessly using Bluetooth technology to external devices like smartphones or computers for processing and control.\", \"hyperparameters\": null, \"input\": \"How is data transmitted from Neuralink devices?\", \"retrieval_context\": [\"---\\n\\n### **Flagship Product: SynapseBand\\u2122**\\n\\nThe SynapseBand is a wearable, non-invasive neural headband that detects and decodes neural activity in real time. It leverages multi-sensor arrays and NeuroLink\\u2019s proprietary NeuralNet Engine\\u2122 to translate thought patterns into actionable digital commands.\\n\\n**Key Features:**\", \"---\\n\\n### **Recent Milestones**\\n\\n* FDA Breakthrough Device Designation for SynapseBand NeuroRehab Protocol (2022)\\n* Launched **NeuroLink SDK 2.0** for developers (Q2 2023)\\n* Partnered with Meta for brain-controlled VR experiences (Q4 2023)\\n* Closed Series E funding of \\\\$310M led by Andreessen Horowitz & SoftBank Vision Fund (Q1 2024)\\n* Published peer-reviewed results in *Nature Neuroscience*, Vol. 29, Issue 7\\n\\n---\\n\\n### **FAQs**\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": true, "score": 1.0, "reason": "The score is 1.00 because the answer was fully relevant and addressed the question directly without any irrelevant information. Great job staying focused and concise!", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"Data is transmitted from Neuralink devices using multi-sensor arrays.\",\n    \"Data is transmitted from Neuralink devices using NeuroLink's proprietary NeuralNet Engine.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": true, "score": 1.0, "reason": "Great job! There are no contradictions, so the actual output is fully aligned with the retrieval context.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"The SynapseBand is a wearable, non-invasive neural headband.\",\n    \"The SynapseBand detects and decodes neural activity in real time.\",\n    \"The SynapseBand uses multi-sensor arrays.\",\n    \"The SynapseBand uses NeuroLink\u2019s proprietary NeuralNet Engine to translate thought patterns into digital commands.\",\n    \"The SynapseBand NeuroRehab Protocol received FDA Breakthrough Device Designation in 2022.\",\n    \"NeuroLink SDK 2.0 was launched for developers in Q2 2023.\",\n    \"NeuroLink partnered with Meta for brain-controlled VR experiences in Q4 2023.\",\n    \"NeuroLink closed Series E funding of $310 million led by Andreessen Horowitz and SoftBank Vision Fund in Q1 2024.\",\n    \"NeuroLink published peer-reviewed results in Nature Neuroscience, Vol. 29, Issue 7.\"\n] \n \nClaims:\n[\n    \"Data is transmitted from Neuralink devices through the use of multi-sensor arrays and NeuroLink's proprietary NeuralNet Engine.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}, "{\"actual_output\": \"Neuralink faces challenges in development such as ensuring accuracy of the thought-to-command system, building a platform for developers to create apps, and collaborating with research hospitals.\", \"context\": null, \"expected_output\": \"Neuralink faces challenges including regulatory approval, ensuring long-term biocompatibility, scaling manufacturing, addressing ethical concerns, and proving clinical efficacy.\", \"hyperparameters\": null, \"input\": \"What challenges does Neuralink face in development?\", \"retrieval_context\": [\"**Q: How accurate is the thought-to-command system?**\\nA: Independent trials report 93\\u201396% accuracy across motor intention, focus detection, and emotional state classification.\\n\\n**Q: Can developers build apps for the platform?**\\nA: Yes, through the NeuroLink SDK and open API marketplace.\\n\\n---\\n\\n### **Media Contacts**\\n\\n[press@neurolink.com](mailto:press@neurolink.com)\\n[investors@neurolink.com](mailto:investors@neurolink.com)\\n\\n---\\n\\n**Company Motto:** *\\u201cWhere Thought Meets Possibility\\u2122\\u201d*\", \"---\\n\\n### **Use Cases**\\n\\n* **Neurorehabilitation:** Assist stroke and spinal cord patients in regaining motor control\\n* **Mental Health:** Monitor and modulate stress, anxiety, and cognitive fatigue\\n* **Education & Training:** Enhance learning through focus optimization and neurofeedback\\n* **Gaming & VR:** Enable thought-controlled interactions in immersive environments\\n* **Workplace Productivity:** Cognitive load monitoring and brain-state optimization\\n\\n---\\n\\n### **Corporate Structure**\\n\\nNeuroLink employs over 1,200 professionals spanning neuroscience, machine learning, hardware engineering, clinical research, and cloud security. The company collaborates with over 45 research hospitals and maintains labs in the U.S., Europe, and Japan.\\n\\n---\\n\\n### **Leadership**\\n\\n* **Dr. Amara Venkatesh** \\u2013 Founder & CEO\\n* **Dr. Julian Ortega** \\u2013 Chief Neuroscience Officer\\n* **Maya Li** \\u2013 VP, AI & Data Science\\n* **Elena Kovacs** \\u2013 Director of Clinical Partnerships\\n* **David Singh** \\u2013 General Counsel\\n\\n---\"]}": {"cached_metrics_data": [{"metric_data": {"name": "Answer Relevancy", "threshold": 0.7, "success": true, "score": 0.75, "reason": "The score is 0.75 because while the answer addresses some challenges Neuralink faces, it includes an irrelevant statement about collaboration with research hospitals, which is not a challenge. This reduces the overall relevancy, but the answer still contains mostly relevant information.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Statements:\n[\n    \"Neuralink faces challenges in development.\",\n    \"Ensuring accuracy of the thought-to-command system is a challenge for Neuralink.\",\n    \"Building a platform for developers to create apps is a challenge for Neuralink.\",\n    \"Neuralink is collaborating with research hospitals.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"yes\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"no\",\n        \"reason\": \"Collaboration with research hospitals is an activity, not a challenge. The statement does not describe a challenge faced in development.\"\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}, {"metric_data": {"name": "Faithfulness", "threshold": 0.7, "success": true, "score": 1.0, "reason": "Great job! There are no contradictions, so the actual output is fully faithful to the retrieval context.", "strictMode": false, "evaluationModel": "gpt-4.1", "evaluationCost": 0, "verboseLogs": "Truths (limit=None):\n[\n    \"NeuroLink employs over 1,200 professionals.\",\n    \"NeuroLink's staff includes experts in neuroscience, machine learning, hardware engineering, clinical research, and cloud security.\",\n    \"NeuroLink collaborates with over 45 research hospitals.\",\n    \"NeuroLink maintains labs in the U.S., Europe, and Japan.\",\n    \"Dr. Amara Venkatesh is the Founder and CEO of NeuroLink.\",\n    \"Dr. Julian Ortega is the Chief Neuroscience Officer at NeuroLink.\",\n    \"Maya Li is the VP of AI & Data Science at NeuroLink.\",\n    \"Elena Kovacs is the Director of Clinical Partnerships at NeuroLink.\",\n    \"David Singh is the General Counsel at NeuroLink.\",\n    \"NeuroLink's thought-to-command system has an independently reported accuracy of 93\u201396% for motor intention, focus detection, and emotional state classification.\",\n    \"Developers can build apps for the NeuroLink platform using the NeuroLink SDK and open API marketplace.\",\n    \"NeuroLink's use cases include neurorehabilitation, mental health, education and training, gaming and VR, and workplace productivity.\",\n    \"NeuroLink's company motto is \u201cWhere Thought Meets Possibility\u2122\u201d.\",\n    \"Media contacts for NeuroLink include press@neurolink.com and investors@neurolink.com.\"\n] \n \nClaims:\n[\n    \"Neuralink faces challenges in development such as ensuring accuracy of the thought-to-command system.\",\n    \"Neuralink faces challenges in building a platform for developers to create apps.\",\n    \"Neuralink faces challenges in collaborating with research hospitals.\"\n] \n \nVerdicts:\n[\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    },\n    {\n        \"verdict\": \"idk\",\n        \"reason\": null\n    }\n]"}, "metric_configuration": {"threshold": 0.7, "evaluation_model": "gpt-4.1", "strict_mode": false, "include_reason": true}}]}}}